Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

BACKGROUND: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment effica...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Thorac Cancer
Κύριοι συγγραφείς: Sugano, Teppei, Seike, Masahiro, Saito, Yoshinobu, Kashiwada, Takeru, Terasaki, Yasuhiro, Takano, Natsuki, Hisakane, Kakeru, Takahashi, Satoshi, Tanaka, Toru, Takeuchi, Susumu, Miyanaga, Akihiko, Minegishi, Yuji, Noro, Rintaro, Kubota, Kaoru, Gemma, Akihiko
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley & Sons Australia, Ltd 2020
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113045/
https://ncbi.nlm.nih.gov/pubmed/32096610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13364
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια